The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to ұDzٲٲ’s report on Genomics in pharma: CRISPR vectors. .
According to ұDzٲٲ’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
CRISPR vectors is a key innovation area in genomics
CRISPR/Cas9 gene editing system works by cutting DNA precisely and allowing natural DNA repair processes to take over. The system consists of two parts, the Cas9 enzyme and a guide RNA. The delivery of CRISPR/Cas9 components into the cell fall into two broad categories, viral and non-viral.
ұDzٲٲ’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 425+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of CRISPR vectors.
Key players in CRISPR vectors – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to CRISPR vectors
Company | Total patents (2021 - 2023) | Premium intelligence on the world's largest companies |
CRISPR Therapeutics | 279 | Unlock Company Profile |
Editas Medicine | 238 | Unlock Company Profile |
Inscripta | 219 | Unlock Company Profile |
E. Merck | 207 | Unlock Company Profile |
Massachusetts General Hospital | 140 | Unlock Company Profile |
Regeneron Pharmaceuticals | 124 | Unlock Company Profile |
Intellia Therapeutics | 118 | Unlock Company Profile |
Beam Therapeutics | 105 | Unlock Company Profile |
Caribou Biosciences | 88 | Unlock Company Profile |
Vertex Pharmaceuticals | 87 | Unlock Company Profile |
Bayer | 74 | Unlock Company Profile |
General Hospital | 74 | Unlock Company Profile |
ToolGen | 68 | Unlock Company Profile |
Arbor Biotechnologies | 67 | Unlock Company Profile |
Sangamo Therapeutics | 65 | Unlock Company Profile |
Bristol-Myers Squibb | 63 | Unlock Company Profile |
Fate Therapeutics | 52 | Unlock Company Profile |
KSQ Therapeutics | 51 | Unlock Company Profile |
Modalis Therapeutics | 50 | Unlock Company Profile |
Jackson ImmunoResearch Laboratories | 48 | Unlock Company Profile |
Seattle Children's Hospital | 46 | Unlock Company Profile |
CIBUS US | 44 | Unlock Company Profile |
Cibus Europe | 42 | Unlock Company Profile |
Danaher | 41 | Unlock Company Profile |
EdiGene | 39 | Unlock Company Profile |
Cellectis | 39 | Unlock Company Profile |
IONTAS | 36 | Unlock Company Profile |
Corteva | 36 | Unlock Company Profile |
Verneuil Participations | 34 | Unlock Company Profile |
Flagship Pioneering | 34 | Unlock Company Profile |
AnGes | 34 | Unlock Company Profile |
G+FLAS Life Sciences | 33 | Unlock Company Profile |
Tropic Biosciences UK | 31 | Unlock Company Profile |
Puretech Health | 31 | Unlock Company Profile |
Intima Bioscience | 31 | Unlock Company Profile |
Keygene | 30 | Unlock Company Profile |
Verve Therapeutics | 30 | Unlock Company Profile |
Fred Hutchinson Cancer Research Center | 29 | Unlock Company Profile |
Application of Information and Communication Technologies (AICT) | 28 | Unlock Company Profile |
Excision BioTherapeutics | 28 | Unlock Company Profile |
Children's Hospital of Philadelphia | 27 | Unlock Company Profile |
Sanofi | 26 | Unlock Company Profile |
Arc Bio | 25 | Unlock Company Profile |
ElevateBio | 24 | Unlock Company Profile |
Royal DSM | 23 | Unlock Company Profile |
SNIPR Biome | 21 | Unlock Company Profile |
Ginkgo Bioworks | 21 | Unlock Company Profile |
Rocket Pharmaceuticals | 21 | Unlock Company Profile |
Illumina | 20 | Unlock Company Profile |
Astellas Pharma | 20 | Unlock Company Profile |
Source: GlobalData Patent Analytics
is the leading patent filer in CRISPR vectors. It is a gene editing company and focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells, ex vivo programs in immuno-oncology, in vivo programs targeting the liver, and additional in vivo programs targeting other organ systems, including muscle and lung.
In terms of application diversity, Illumina is the top company, followed by Keygene and Danaher.
By means of geographic reach, Application of Information and Communication Technologies (AICT) holds the top position. Intima Bioscience and Cibus Europe stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access ұDzٲٲ’s latest thematic research report on .
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, ұDzٲٲ’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.